Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms ARM-TD
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2019 According to a Teva Pharmaceutical Industries media release, data from analysis of AIMS Global Judgment Components (Items 8-10) in patients with TD from the ARM-TD and AIM-TD studies will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
    • 31 Aug 2017 According to a Teva Pharmaceutical Industries media release, based on the results from AIM-TD and ARM-TD studies, the U.S. Food and Drug Administration (FDA) has approved AUSTEDO (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
    • 08 Jun 2017 Results (n=259) of pooled analysis of ARM-TD and AIM-TD studies assessing efficacy and safety of deutetrabenazine in reducing the severity of abnormal involuntary movements presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top